Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
  1. Home
  2. Stock
  3. CNC
CNC logo

CNC Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Centene Corp (CNC) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
36.140
1 Day change
-0.71%
52 Week Range
66.030
Analysis Updated At
2026/03/06
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

Centene Corp (CNC) is not a strong buy at the moment for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock is facing significant financial challenges, as evidenced by its negative net income and declining EPS. While there are some positive developments in affordable housing projects and analyst optimism about future Medicaid and Medicare margins, the lack of strong trading signals, mixed analyst ratings, and weak financial performance make this stock a hold rather than a buy.

Technical Analysis

The technical indicators are mixed. The MACD is positive but contracting, the RSI is neutral at 48.123, and the moving averages are bullish (SMA_5 > SMA_20 > SMA_200). The stock is trading near its pivot level of 43.519, with support at 42.203 and resistance at 44.835. However, the recent price drop of -3.82% in regular trading and -0.76% in pre-market suggests bearish momentum.

Options Data

Bullish
Open Interest Put-Call Ratio
Bearish
Option Volume Put-Call Ratio

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
18
Buy
4

Positive Catalysts

  • Analysts have raised price targets recently, with some firms like Truist and Barclays expressing optimism about margin recovery and ACA exchange opportunities.

  • Positive developments in affordable housing projects, which could improve community health outcomes and enhance Centene's reputation.

Neutral/Negative Catalysts

  • Weak Q4 financial performance with a significant drop in net income (-489.05% YoY) and EPS (-500% YoY).

  • Concerns about Medicaid and ACA exchange visibility in 2026, as highlighted by analysts like Wells Fargo.

  • No recent significant hedge fund, insider, or congressional trading activity to indicate confidence in the stock.

Financial Performance

Centene's Q4 2025 financials show revenue growth of 21.86% YoY to $49.725 billion, but net income dropped to -$1.101 billion, and EPS fell to -2.24. Gross margin also declined significantly to 4.3%, down 48.50% YoY. These figures indicate financial instability and poor profitability.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Analyst ratings are mixed. While some firms like Truist and Barclays are bullish with price targets of $49 and $54, others like Wells Fargo and Deutsche Bank maintain neutral or hold ratings with lower targets. The consensus suggests cautious optimism but highlights significant challenges in the near term.

Wall Street analysts forecast CNC stock price to rise
15 Analyst Rating
Wall Street analysts forecast CNC stock price to rise
5 Buy
8 Hold
2 Sell
Hold
Current: 36.400
sliders
Low
32
Averages
43.07
High
59
Current: 36.400
sliders
Low
32
Averages
43.07
High
59
Mizuho
Neutral
downgrade
$47 -> $41
AI Analysis
2026-03-11
New
Reason
Mizuho
Price Target
$47 -> $41
AI Analysis
2026-03-11
New
downgrade
Neutral
Reason
Mizuho lowered the firm's price target on Centene to $41 from $47 and keeps a Neutral rating on the shares. The firm updated the company's model post the Q4 report. Centene shares were down 14% following the company's comments at a competitor's conference yesterday, the analyst tells investors in a research note. Mizuho cites a more conservative valuation multiple pending greater clarity on the potential risk shifts if health insurance exchange dis-enrollment is worse than expectations for the target cut.
Morgan Stanley
Equal Weight
maintain
$38 -> $45
2026-03-04
Reason
Morgan Stanley
Price Target
$38 -> $45
2026-03-04
maintain
Equal Weight
Reason
Morgan Stanley raised the firm's price target on Centene (CNC) to $45 from $38 and keeps an Equal Weight rating on the shares. Q4 results were "challenged, but relatively cleaner" than peer Molina Healthcare (MOH), the analyst tells investors. Centene expects stable Medicaid margins in 2026 driven by a trend similar to levels in 2025, which the firm calls "more prudent."
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for CNC
Unlock Now

People Also Watch